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Abstract
Purpose: The aim of this article was to describe recent advanc-
es in the use of new technology in diabetic retinopathy screen-
ing by looking at studies that assessed the effectiveness and 
cost-effectiveness of these technologies. Methods: The author 
conducts an ongoing search for articles relating to screening or 
management of diabetic retinopathy utilising Zetoc with key-
words and contents page lists from relevant journals. Results: 
The areas discussed in this article are reference standards, alter-
natives to digital photography, area of retina covered by the 
screening method, size of the device and hand-held cameras, 
mydriasis versus non-mydriasis or a combination, measure-
ment of distance visual acuity, grading of images, use of auto-
mated grading analysis and cost-effectiveness of the new tech-
nologies. Conclusions: There have been many recent advances 
in technology that may be adopted in the future by screening 
programmes for sight-threatening diabetic retinopathy but 
each device will need to demonstrate effectiveness and cost-
effectiveness before more widespread adoption.
© 2019 The Author(s) 
Published by S. Karger AG, Basel
Introduction
The Wilson and Junger criteria, which are the 1968 
principles [1] applied by the World Health Organisation, 
have formed the basis of development of screening pro-
grammes and required an evidence base which I adapted 
[2] for sight-threatening diabetic retinopathy (STDR): 
1. STDR is an important public health problem [3, 4]
2. The incidence of STDR is going to remain the same or 
become an even greater public health problem [5, 6]
3. STDR has a recognisable latent or early symptomatic 
stage [7–9]
4. Treatment for STDR is effective and agreed upon uni-
versally
Diabetic retinopathy (DR) can be prevented or the rate 
of deterioration reduced by improved control of blood 
glucose [10–12] and blood pressure [13, 14]. Laser treat-
ment is effective [15, 16], and vascular endothelial growth 
factor inhibitors can improve the results of treatment in 
diabetic maculopathy [17, 18] and in some cases of pro-
liferative DR [19, 20].
In this article I have concentrated on reviewing the up-
dates in relation to the final two criteria:
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5. The test – a suitable and reliable screening test is avail-
able, acceptable to both health care professionals and 
(more importantly) to the public
6. Cost-effectiveness – the costs of screening and effec-
tive treatment of STDR are balanced economically in 
relation to total expenditure on health care – including 
the consequences of leaving the disease untreated
Methodology
The review of the literature relating to screening for DR has 
been ongoing since March 2000. The methodology involves a 
search technique for articles relating to screening or management 
of DR utilising Zetoc (http://zetoc.jisc.ac.uk/), which is a compre-
hensive research database, giving you access to over 34,500 jour-
nals and more than 55 million article citations and conference pa-
pers through the British Library’s electronic table of contents cov-
ering 1993 to the present day and is updated daily.
Subject title keywords are searched daily using 21 different 
combinations (e.g., “retinopathy” or “digital” and “imaging” and 
“eye” in title), and contents page lists from 28 journals are reviewed 
monthly. Articles of interest identified with this search strategy 
were sourced from online electronic journal resources (e.g., Open 
Athens [21] or the Royal Society of Medicine [22]).
Results
The Test
Reference Standards for Digital Photographic and 
Other Screening Methods
There are two accepted reference standards to com-
pare with any new screening methodology.
(a) 7-field (30-degree) stereo photography is consid-
ered the best reference standard. 
The advantage of this reference standard is the area of 
retina covered and the detailed grading classification [23] 
which has been developed for this standard. The disad-
vantage is that the unassessable image rate is at 10% in one 
report from the Wisconsin Epidemiological Study of Dia-
betic Retinopathy [24] and, in many studies, not reported 
so is likely higher than that rate.
(b) Slit lamp biomicroscopy by an ophthalmologist is 
another accepted reference standard, although it is prefer-
able with this methodology to use one or a small number of 
retinal specialists. The studies demonstrate significant vari-
ation compared to 7-field stereophotography with some 
studies in which the ophthalmologists performed poorly 
[25, 26], and others with better results [27, 28]. Gangaputra 
et al. [29] compared evaluation by clinical examination 
with image grading at a reading centre for the classification 
of DR and diabetic macular oedema and concluded that the 
results support the use of clinical information for defining 
broad severity categories but not for documenting small-
to-moderate changes in DR over time.
Gangaputra et al. [30] also compared 35-mm film with 
digital photography and found that agreement between 
film and digital images was substantial to almost perfect 
for DR severity level and moderate to substantial for dia-
betic macular oedema and clinically significant macular 
oedema severity levels, respectively. The study concluded 
that replacement of film fundus images with digital im-
ages for DR severity level should not adversely affect clin-
ical trial quality.
The “Exeter Standards,” which were a consensus view 
formed at a meeting [31] in Exeter in the UK in 1988, 
formed the basis for a publication [32] for an acceptable 
method for use in a systematic screening programme for 
DR in the UK, which was adopted in the planning [33] of 
the English NHS Diabetic Eye Screening Programme. 
The Exeter Standards recommended that a screening test 
for STDR should achieve a minimum sensitivity of 80% 
and a minimum specificity of 95%.
A systematic review by Piyasena et al. [34] found that 
both mydriatic and non-mydriatic digital imaging meth-
ods generate a satisfactory level of sensitivity. The mean 
proportion of ungradable images in non-mydriatic meth-
ods was 18.4% (CI 13.6–23.3%) and for the mydriatic 
method 6.2% (CI 1.7–10.8%) and, once these were ex-
cluded from analysis:
(a) the 1-field non-mydriatic strategy gave summary 
estimates of sensitivity of 78% (CI 76–80%) and of speci-
ficity of 91% (CI 90–92%); the 2-field non-mydriatic 
strategy gave summary estimates of sensitivity of 91% 
(95% CI 90–93%) and of specificity of 94% (CI 93–95%);
(b) the 1-field mydriatic strategy gave summary esti-
mates of sensitivity of 80% (CI 77–82%) and of specificity 
of 93% (CI 92–94%); the 2-field mydriatic strategy gave 
summary estimates of sensitivity of 85% (95% CI 84–
87%) and of specificity of 82% (95% CI 81–83%).
The article concluded that, overall, there was no differ-
ence in sensitivity between non-mydriatic and mydriatic 
methods (86%, 95% CI 85–87%) after exclusion of un-
gradable images.
In the literature, studies vary as to whether they count 
ungradable images as test positive, and it is more likely 
that a study will achieve the 95% specificity if they do not 
count ungradable images as test positive.
Alternatives to Digital Photography
Goh et al. [35] produced a comprehensive review of ret-
inal imaging techniques for DR screening. The most excit-
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ing new technologies that may be used in screening in the 
future, providing they can be shown to be effective and cost-
effective, are the scanning confocal ophthalmoscopes that 
use either laser light or light-emitting diodes (LED). Exam-
ples of 4 CE-marked scanning confocal ophthalmoscopes 
that are currently commercially available are discussed:
The Optos California which is described as ultrawide-
field imaging incorporates low-powered laser wave-
lengths in red (635 nm), green (532 nm) and blue (488 
nm) that scan simultaneously and produce a composite 
image that joins the 3 wavelengths of light into a false-
colour image. In 2016, Silva et al. [36] compared the ef-
ficiency of non-mydriatic ultrawide-field imaging and 
non-mydriatic fundus photography in a DR ocular tele-
health programme.
The Heidelberg Spectralis OCT2 with multicolour 
functionality also uses three laser wavelengths, blue (488 
nm), green (515 nm) and infrared reflectance (820 nm), to 
simultaneously capture a composite false-colour image.
The Eidon confocal scanner (Centervue, Padova, Ita-
ly) combines confocal imaging with natural white-light 
illumination to provide a true-colour image using a white 
LED (440–650 nm).
The Zeiss Clarus 500 uses red (585–640 nm), green 
(500–585 nm) and blue (435–500 nm) LEDs to capture a 
composite image.
There have not yet been any major studies published 
using any of these imaging techniques in a DR screening 
setting.
The Area of Retina Covered by the Screening Method
The original 35-mm film fundus cameras that were 
used for 7-field stereophotography had 30-degree fields. 
In 1989, Moss et al. [24] demonstrated that for 8 retinop-
athy levels, the rate of agreement with 7 stereoscopic 
fields ranges from 80% for two 30-degree stereo fields to 
91% for four 30-degree stereo fields. 
The non-mydriatic digital fundus cameras that are 
widely used in screening programmes, whether or not the 
patient’s eyes are dilated, usually have 45-degree fields. 
Population-based screening programmes that utilise 
non-mydriatic photography commonly capture a single 
45-degree field centred on the fovea of each eye [37]. For 
many mydriatic schemes, two 45-degree fields are taken 
[38] – one centred on the fovea and one on the optic disc. 
The Scanning Confocal Ophthalmoscopes have the 
fields of view shown below: 
(a) Heidelberg Spectralis OCT2 with multicolour function-
ality: 1-field or 2-field non-mydriatic 55-degree 
image(s) per eye (when using supplementary lens) 
(b) Optos California: 1-field non-mydriatic 200-degree 
image per eye
(c) Zeiss Clarus 500: 1-field non-mydriatic 130-degree 
image per eye
(d) CentreVue Eidon: 1- or 2-field non-mydriatic 60-de-
gree image(s) per eye
Size of the Device and Hand-Held Cameras
There have been many claims for the use of smart-
phones in DR screening. There is an excellent review of 
potential devices by Bolster et al. [39]. Hand-held devices 
have historically performed poorly in DR screening [40] 
although a recent study suggested that they could be used 
for optic disc imaging [41] and another study suggested 
that a small device had been validated [42] for DR screen-
ing. The latter was an excellent study that compared the 
sensitivity and specificity of a “fundus on phone” camera, 
a smartphone-based retinal imaging system, as a screen-
ing tool for DR detection and DR severity in comparison 
with 7-standard field digital retinal photography. It was 
noteworthy that mydriasis was used and that the smart-
phone was fixed and the patient’s head positioned using 
a slit lamp chin rest, overcoming many of the problems of 
movement of patient and operator that is associated with 
hand-held devices. It may be that the way forward with 
these small devices is to use an inexpensive device to fix 
them and a slit lamp chin rest for the patient.
Mydriasis versus Non-Mydriasis or a Combination 
of Both
A strong correlation has been reported [43] between 
older age and poor-quality image rate in non-mydriatic 
digital photography in DR screening. The main reason 
for this is higher rates of media opacity and smaller pupil 
sizes in older people. Scanlon et al. [44] reported an un-
gradable image rate for non-mydriatic photography of 
19.7% (95% CI 18.4–21.0%), and Murgatroyd et al. [45] 
reported an ungradable image rate for non-mydriatic 
photography of 26%. The mean age of the patients in the 
study of Scanlon et al. [44] was 65 years, and in that of 
Murgatroyd et al. [45] the median age of the patients was 
63.0 years (range 17–88 years, interquartile range 51.8–
70.3 years). There is also an ethnicity component with 
some studies demonstrating poorer results for non-myd-
riatic digital photographic screening in eyes with more 
iris pigmentation [46]. Scotland introduced the concept 
of staged mydriasis into their screening programme, only 
dilating those who the technician taking the images de-
termined had poor-quality images without mydriasis. As 
the age of the Scottish population has increased, the num-
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bers needing dilation have risen to 34% [pers. commun. 
Mike Black, Scottish DRS Collaborative Coordinator]. 
Silva et al. [47] have demonstrated that the ungradable 
rate per patient for DR and diabetic macular oedema was 
significantly lower with non-mydriatic ultrawide-field 
imaging compared with non-mydriatic fundus photogra-
phy (DR, 2.8 vs. 26.9%, p < 0.0001; diabetic macular oe-
dema, 3.8 vs. 26.2%, p < 0.0001) in the Indian Health Ser-
vice-JVN programme, which serves American Indian and 
Alaska Native communities.
Measurement of Distance Visual Acuity
Visual acuity is widely accepted as an adjunct to screen-
ing for diabetic maculopathy, but in isolation it is not suf-
ficiently sensitive to be a screening tool [48, 49], and there 
is currently no study that supports the added benefit of 
visual acuity in screening. It is however, from the patient’s 
perspective, probably the most important factor.
Grading the Images
In most screening programmes, trained graders grade 
the images, and the ones with the severer pathology are 
referred to ophthalmologists to decide on further man-
agement. Different grading criteria are used in different 
countries.
Use of Automated Analysis for Grading
Automated grading of images from DR screening has 
been pioneered in Scotland with the development of iGrad-
ingM (Scottish Health Innovations Ltd.) which has been 
used extensively as first level disease/no disease grader [50]. 
This includes an image quality assessment to reduce the 
workload of manual grading in the Scottish screening pro-
gramme which takes 1-field non-mydriatic photographs.
Tufail et al. [51] reported on a study which included a 
total of 20,258 patients with 102,856 two-field per eye im-
ages. Three software products were tested, iGradingM 
(Scottish Health Innovations Ltd.), EyeArt (Eyenuk Inc., 
Woodland Hills, CA, USA) and Retmarker (Retmarker 
Ltd., Coimbra, Portugal), with the following sensitivities: 
EyeArt 94.7% (95% CI 94.2–95.2%) for any retinopathy 
(manual grades R1, U, M1, R2 and R3 as refined by arbi-
tration), 93.8% (95% CI 92.9–94.6%) for referable reti-
nopathy; corresponding sensitivities for Retmarker were 
73.0% (95% CI 72.0–74.0%) for any retinopathy, 85.0% 
(95% CI 83.6–86.2%) for referable retinopathy. For man-
ual grades R0 and no maculopathy (M0), specificity was 
20% (95% CI 19–21%) for EyeArt and 53% (95% CI 52–
54%) for Retmarker. In this study the version of iGrad-
ingM was unable to grade the nasal field.
The Iowa Detection Program (IDx-DR) is another soft-
ware solution for automated grading that was tested [52] 
in the Hoorn Diabetes Care System in the Netherlands.
There are also a number of developing systems [53, 54] 
that are not yet commercially available.
Automated analysis of OCT images through use of 
deep learning is being explored in a collaborative project 
between Moorfields Eye Hospital and Google DeepMind 
[55] and in the Singapore Eye Research Centre [35].
A recent study [56] examined the variability in differ-
ent methods of grading, definitions of reference stan-
dards, and their effects on building deep learning models 
for the detection of diabetic eye disease. The results from 
the studies are very dependent on the image sets that they 
are being tested upon.
Cost-Effectiveness
The cost-effectiveness of screening for STDR is depen-
dent on the local health care system but there are various 
reports of screening being cost-effective in health care set-
tings such as Singapore [57], Canada [58], South Africa 
[59] and India [60] with the proviso that low-risk groups 
can be identified and cost-effectiveness of screening for 
STDR can be improved in some settings by differential or 
individualised screening intervals for low- and high-risk 
groups [61–63]. Automated grading was shown to be cost-
effective in the Scottish Screening Programme [64, 65], 
and the Tufail study [51] reported that two of the software 
packages that they tested (Retmarker and EyeArt) achieved 
acceptable sensitivity for referable retinopathy and false-
positive rates (compared with human graders as reference 
standard) and appear to be cost-effective.
The use of OCT in screening has been considered but 
the cost of the equipment makes it more likely that this 
would only be useful as a second-line screening tool [66, 
67] for those who are screen positive with 2-dimensional 
photographic markers for diabetic maculopathy.
With respect to the use of ultrawide-field imaging sys-
tems in DR screening programmes, a review by Fenner et 
al. [68] summed up the current situation that, despite the 
impressive outcomes in clinical trials, it remains unclear 
whether the cost savings of reduced inappropriate refer-
rals are sufficient to justify the financial outlay.
Discussion/Conclusion
There have been many recent advances in technology 
that may be adopted by screening programmes for STDR 
in the future.
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Most screening programmes currently use staged 
mydriasis with one 45-degree field non-mydriatic digi-
tal photography or two 45-degree field mydriatic digital 
photography. Advances in camera technology and in 
particular scanning confocal ophthalmoscopes with la-
ser light or light-emitting diodes show good potential 
for non-mydriatic photography with wider fields. Each 
device will need to demonstrate effectiveness and cost-
effectiveness before more widespread adoption. Auto-
mated reading of images is progressing, with Scotland 
having already introduced this into their national pro-
grammes and other countries likely to follow in the fu-
ture.
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